Biogen Inc.

Contributing Author

Recent Articles by Biogen Inc.

Sep-03	Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) BIIB GlobeNewswire
Sep-03	LEQEMBI (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer's Disease Approved in China BIIB GlobeNewswire
Sep-01	Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) BIIB GlobeNewswire
Aug-31	Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI (lecanemab) for Early Alzheimer's Disease BIIB GlobeNewswire
Aug-24	LEQEMBI IQLIK (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease BIIB GlobeNewswire
Aug-06	Biogen Completes Acquisition of RayThera Inc. BIIB GlobeNewswire
Aug-06	Biogen Completes Acquisition of RayThera Inc. BIIB GlobeNewswire
Jul-15	Biogen Appoints Michael J. Parini as Chief Legal Officer BIIB GlobeNewswire
Jul-14	LEQEMBI Real-World LEADER Study Presented at AAIC 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment BIIB -8.17% GlobeNewswire
Jul-14	Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease BIIB -8.17% GlobeNewswire
Jul-13	FDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease BIIB GlobeNewswire
Jul-12	LEQEMBI Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference (AAIC) 2026 BIIB GlobeNewswire
Jun-29	Biogen to Highlight Breadth of Alzheimer's Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen BIIB GlobeNewswire
Jun-17	Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc. BIIB GlobeNewswire
Jun-04	Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy BIIB GlobeNewswire
Jun-04	EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus BIIB GlobeNewswire
Jun-03	Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses BIIB GlobeNewswire
May-21	Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease BIIB GlobeNewswire
May-14	Biogen Completes Acquisition of Apellis Pharmaceuticals BIIB -6.43% GlobeNewswire
May-14	Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer's Disease BIIB -6.43% GlobeNewswire
May-08	Update on FDA Priority Review of LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease BIIB GlobeNewswire
Apr-20	Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region BIIB GlobeNewswire
Mar-31	Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology BIIB GlobeNewswire
Mar-30	FDA Approves New High Dose Regimen of SPINRAZA (nusinersen) for Spinal Muscular Atrophy BIIB GlobeNewswire
Mar-28	Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity BIIB GlobeNewswire
Mar-20	Results from Real-World, Long-Term Treatment Persistence with LEQEMBI (lecanemab-irmb) in the United States Presented at AD/PD 2026 BIIB GlobeNewswire
Mar-19	Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting BIIB GlobeNewswire
Mar-11	Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy BIIB GlobeNewswire
Mar-05	Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences BIIB GlobeNewswire
Mar-04	The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome BIIB GlobeNewswire
Feb-11	Biogen Announces Board Chair Transition BIIB GlobeNewswire
Feb-08	Biologics License Application for Subcutaneous Formulation of "LEQEMBI" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China BIIB GlobeNewswire
Feb-04	Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy BIIB GlobeNewswire
Jan-28	Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options BIIB GlobeNewswire
Jan-25	FDA Accepts LEQEMBI IQLIK (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review BIIB GlobeNewswire
Jan-12	Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA (nusinersen) for Spinal Muscular Atrophy BIIB GlobeNewswire
Jan-05	Biologics License Application for Subcutaneous Formulation of "LEQEMBI" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China BIIB GlobeNewswire
Dec-22	The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS BIIB GlobeNewswire
Dec-08	"LEQEMBI" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List BIIB GlobeNewswire
Dec-05	Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting BIIB GlobeNewswire
Dec-03	Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 BIIB GlobeNewswire
Dec-02	New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF BIIB GlobeNewswire
Dec-01	Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting BIIB GlobeNewswire
Nov-27	Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI" for the Treatment of Early Alzheimer's Disease in Japan BIIB GlobeNewswire
Nov-24	Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions BIIB GlobeNewswire
Nov-20	Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer's Disease Conference BIIB GlobeNewswire
Nov-17	Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments BIIB GlobeNewswire
Nov-17	High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy BIIB GlobeNewswire
Nov-14	Biogen Completes Acquisition of Alcyone Therapeutics BIIB GlobeNewswire
Nov-13	"LEQEMBI" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom BIIB GlobeNewswire
Nov-03	Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025 BIIB GlobeNewswire
Oct-26	Health Canada Grants Authorization for "LEQEMBI" (lecanemab) for the Treatment of Early Alzheimer's Disease BIIB GlobeNewswire
Oct-24	Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio BIIB GlobeNewswire
Oct-22	Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025 BIIB GlobeNewswire
Oct-13	LEQEMBI IQLIK(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" BIIB GlobeNewswire
Oct-09	Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome BIIB GlobeNewswire
Oct-06	Eisai and Biogen Announce U.S. Availability of LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease BIIB GlobeNewswire
Sep-28	"LEQEMBI" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China BIIB GlobeNewswire
Sep-24	LEQEMBI (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia BIIB GlobeNewswire
Sep-23	Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen BIIB GlobeNewswire
Sep-18	Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates BIIB GlobeNewswire
Sep-17	Biogen Receives European Commission Approval for ZURZUVAE (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe BIIB GlobeNewswire
Sep-02	Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI IQLIK (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status BIIB +5.60% GlobeNewswire
Sep-02	Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome BIIB +5.60% GlobeNewswire
Aug-29	FDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease BIIB GlobeNewswire
Aug-25	Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress BIIB GlobeNewswire
Aug-25	Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI (lecanemab) BIIB GlobeNewswire
Aug-11	Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome BIIB GlobeNewswire
Jul-30	Two-Year Real-World Study of LEQEMBI in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025 BIIB GlobeNewswire
Jul-25	ZURZUVAE (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression BIIB GlobeNewswire
Jul-21	Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025 BIIB GlobeNewswire
Jul-21	Biogen Announces $2 Billion Manufacturing Investment in North Carolina's Research Triangle Park in Conjunction with its 30th Anniversary BIIB GlobeNewswire
Jul-10	Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress BIIB GlobeNewswire
Jun-30	Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy BIIB GlobeNewswire
Jun-27	New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA BIIB GlobeNewswire
Jun-25	Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results BIIB GlobeNewswire
Jun-18	Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia BIIB GlobeNewswire
Jun-12	Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity BIIB GlobeNewswire
May-27	Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies BIIB GlobeNewswire

Biogen Inc.

Recent Articles by Biogen Inc.

Upgrade your Finviz experience